This database contains 57 studies, archived under the term: "donepezil"
Click here to filter this large number of results.
Cognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe disease
Background/aims: Cognitive and functional decline define the transition from moderate to severe Alzheimer’s disease (AD); however, specific relationships between deteriorating cognition and functional abilities are less well characterized. Such relationships are important in care planning and understanding patient needs. Objectives of this post hoc analysis of data from a multicenter randomized double-blind placebo-controlled study were […]
Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project
Satoh, Masayuki,
Ishikawa, Hiroyasu,
Meguro, Kenichi,
Kasuya, Masashi,
Ishii, Hiroshi,
Yamaguchi, Satoshi
Deficits in the cholinergic system are pronounced in dementia with Lewy bodies (DLB) and are more severe in patients with visual hallucinations (VHs). The aim is to identify the occipital glucose metabolism patterns by positron emission tomography (PET) and the changes following donepezil treatment. 13 DLB patients with VHs were enrolled in the study. After […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Plasma concentration of donepezil to the therapeutic response of Alzheimer’s disease in Taiwanese
Yang, Yuan-Han,
Wu, Shey-Lin,
Chou, Mei-Chuan,
Lai, Chiou-Lian,
Chen, Su-Hwei,
Liu, Ching-Kuan
Donepezil has been approved for the treatment for mild-to-moderate Alzheimer’s disease (AD), but the therapeutic response rate varies from 20 to 60%. A higher oral dosage was suggested to have a better therapeutic response in reported results, but the plasma concentration of donepezil was not examined with respect to the therapeutic outcomes in those studies. […]